C Pitt1, L Sanchez-Ramos, A M Kaunitz. 1. Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Florida Health Science Center, Jacksonville, Florida 32209, USA.
Abstract
OBJECTIVE: To estimate the efficacy of preoperative administration of intravaginal metronidazole for the prevention of postcesarean endometritis. METHODS: This double-masked, placebo-controlled randomized trial included patients of at least 24 weeks' gestation undergoing cesarean deliveries for various indications. Patients were randomized to receive either 5 g of metronidazole gel intravaginally or matching placebo before the initiation of the cesarean. All patients underwent surgical cleansing of the abdomen, and most received prophylactic antibiotics after cord clamping. Patients with chorioamnionitis and/or suspected allergy to metronidazole were excluded. For a two-sided alpha of 0.05 and beta of 0.20 (80% power), 120 subjects were required in each group. The main outcome variable was the incidence of postcesarean endometritis. Secondary outcome variables included presence of febrile morbidity, wound infection, days on antibiotics, and length of postpartum hospitalization. Neonatal outcomes included birth weight, Apgar scores less than 7 at 5 minutes, umbilical arterial pH less than 7.16, admission and length of stay in the neonatal intensive care unit, and length of hospital stay. RESULTS: Of 112 patients receivingmetronidazole, eight (7%) developed postcesarean endometritis, compared with 19 of 112 (17%) of those receiving placebo gel (relative risk 0.42, 95% confidence interval 0.19, 0.92). No significant differences were noted between treatment groups with respect to the other outcome variables. CONCLUSION: The preoperative administration of 5 g of intravaginal metronidazole gel appears to reduce the incidence of postcesarean endometritis.
RCT Entities:
OBJECTIVE: To estimate the efficacy of preoperative administration of intravaginal metronidazole for the prevention of postcesarean endometritis. METHODS: This double-masked, placebo-controlled randomized trial included patients of at least 24 weeks' gestation undergoing cesarean deliveries for various indications. Patients were randomized to receive either 5 g of metronidazole gel intravaginally or matching placebo before the initiation of the cesarean. All patients underwent surgical cleansing of the abdomen, and most received prophylactic antibiotics after cord clamping. Patients with chorioamnionitis and/or suspected allergy to metronidazole were excluded. For a two-sided alpha of 0.05 and beta of 0.20 (80% power), 120 subjects were required in each group. The main outcome variable was the incidence of postcesarean endometritis. Secondary outcome variables included presence of febrile morbidity, wound infection, days on antibiotics, and length of postpartum hospitalization. Neonatal outcomes included birth weight, Apgar scores less than 7 at 5 minutes, umbilical arterial pH less than 7.16, admission and length of stay in the neonatal intensive care unit, and length of hospital stay. RESULTS: Of 112 patients receiving metronidazole, eight (7%) developed postcesarean endometritis, compared with 19 of 112 (17%) of those receiving placebo gel (relative risk 0.42, 95% confidence interval 0.19, 0.92). No significant differences were noted between treatment groups with respect to the other outcome variables. CONCLUSION: The preoperative administration of 5 g of intravaginal metronidazole gel appears to reduce the incidence of postcesarean endometritis.
Authors: R F Lamont; J D Sobel; J P Kusanovic; E Vaisbuch; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero Journal: BJOG Date: 2011-01 Impact factor: 6.531
Authors: Kim A Boggess; Alan Tita; Victoria Jauk; George Saade; Sherri Longo; Erin A S Clark; Sean Esplin; Kristin Cleary; Ronald Wapner; Kelli Letson; Michelle Owens; Sean Blackwell; Carmen Beamon; Jeffrey M Szychowski; William Andrews Journal: Obstet Gynecol Date: 2017-03 Impact factor: 7.661
Authors: Alan T N Tita; Jeff M Szychowski; Kim Boggess; George Saade; Sherri Longo; Erin Clark; Sean Esplin; Kirsten Cleary; Ron Wapner; Kellett Letson; Michelle Owens; Adi Abramovici; Namasivayam Ambalavanan; Gary Cutter; William Andrews Journal: N Engl J Med Date: 2016-09-29 Impact factor: 91.245
Authors: Mauricio La Rosa; Victoria Jauk; George Saade; Kim Boggess; Sherri Longo; Erin A S Clark; Sean Esplin; Kirsten Cleary; Ronald Wapner; Kellett Letson; Michelle Y Owens; Sean Blackwell; Jeff M Szychowski; William W Andrews; Alan T Tita Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: Alan T N Tita; Dwight J Rouse; Sean Blackwell; George R Saade; Catherine Y Spong; William W Andrews Journal: Obstet Gynecol Date: 2009-03 Impact factor: 7.661
Authors: Shraddha M Pore; Suman P Sardesai; Vinay S Tapare; Meghana V Kulkarni; Ankur P Malhotra; Chandrashekhar S Chavan Journal: Indian J Pharmacol Date: 2012-03 Impact factor: 1.200